MED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medifast Inc (MED) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of significant trading signals, and weak growth prospects make it prudent to hold off on investing in this stock currently.
The MACD is slightly positive but contracting, indicating a lack of strong momentum. RSI is neutral at 68.226, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point (10.615), with resistance at 11.047 and support at 10.183.
Insiders are buying, with a significant increase of 3472.36% in insider buying over the last month.
Analyst sentiment is neutral, with a lowered price target and no clear growth drivers identified.
In Q4 2025, Medifast reported a revenue drop to $75.1M (-36.90% YoY), net income of -$18.1M (-2362.05% YoY), and EPS of -1.65 (-2457.14% YoY). Gross margin also declined to 69.43% (-6.34% YoY), indicating significant financial struggles.
Stephens lowered the price target from $15 to $12 and maintained an Equal Weight rating, citing the need for growth in the coach count as a key proof point.
